Knee Implant Prices Remain Steady, Offering Relief to Patients

New Delhi, November 14 (Daily Kiran) : The National Pharmaceutical Pricing Authority (NPPA) has announced an extension of the maximum price cap for orthopedic knee implants until January 15, 2027. This decision comes as a relief to patients, as the deadline was originally set to expire on November 15, 2026.

The NPPA’s move to prolong the current pricing regulations was influenced by representations from manufacturers and industry associations. The price cap for knee implants was first established on August 16, 2017, and has seen periodic adjustments since then.

In addition to the knee implants, the NPPA has instructed close monitoring of the implementation of trade margin rationalization (TMR) for 137 non-scheduled anti-cancer drugs. Revised prices for these medications took effect on November 9.

According to a statement from the Ministry of Chemicals and Fertilizers, the latest revised price list, compiled from data provided by companies by November 11, is available on the NPPA’s website and the ‘Pharma Sahi Daam’ platform.

All manufacturers, retailers, dealers, stockists, hospitals, and medical institutions have been directed to comply with the updated prices and display the revised price list prominently on their premises and websites.

An official fact sheet indicates that this price cap will lead to an annual savings of approximately ₹3,502.31 crore for consumers. It also notes that prices of over 1,000 different branded drugs have seen significant reductions.

A total of 76 pharmaceutical companies have reported revised maximum retail prices (MRP) for 1,225 formulations related to 121 anti-cancer drugs. State drug controllers are tasked with ensuring compliance among manufacturers, dealers, hospitals, and medical institutions to ensure that the benefits of the revised MRP reach patients. The statement warns that any violations could result in actions for overcharging under the provisions of the DCP, 2013.